Marshall Wace
TELA icon

Marshall Wace’s TELA Bio TELA Stock Holding History

Marshall Wace’s Portfolio TELA Stock Details TELA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-106,804
Closed -$270K – 3001
2024
Q3 		$270K Buy
+106,804
New +$380K ﹤0.01% 2194

Other funds holding TELA

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Marshall Wace's TELA Position: Q4 2024 in Review

Marshall Wace sold out of TELA Bio (TELA) in Q4 2024, closing a stake of 106,804 shares — an estimated $270K sold.

Marshall Wace first reported a position in TELA in Q3 2024 and held it in 1 quarter. The position peaked at $270K in Q3 2024. 47 funds tracked by Wall St. Rank hold TELA as of Q4 2024.

  • Marshall Wace reported no remaining TELA Bio position as of Q4 2024 after selling out during the quarter.
  • Marshall Wace sold 106,804 TELA Bio shares in Q4 2024, an estimated $270K.
  • Marshall Wace first reported a position in TELA Bio in Q3 2024 and held it in 1 quarter.
  • Marshall Wace's TELA Bio position peaked at $270K in Q3 2024.
  • 47 funds tracked by Wall St. Rank held TELA Bio as of Q4 2024.

Based on Marshall Wace's 13F filing for Q4 2024, filed 13 Feb 2025.